



September 5, 2025

To whom it may concern

Company: SUNDRUG CO., LTD.
Representative: Hiroshi Sadakata,
CEO and Representative Director
(Code number: 9989; Tokyo Stock Exchange, Prime Market)
Contact: Yoshinobu Kato,
General Manager,
Administrative Division
TEL: +81-42-369-6211

**Notice Regarding Revision of Non-consolidated Financial Results Forecasts for the Six Months
Ending September 30, 2025 and the Fiscal Year Ending March 31, 2026**

SUNDRUG CO., LTD. (the “Company”) hereby announces that it has revised its non-consolidated financial result forecasts for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026), released on May 15, 2025, as described below.

1. Revised non-consolidated financial forecasts for the six months ending September 30, 2025 (April 1, 2025 to September 30, 2025)

(Units: million yen, %)

	Net sales	Operating profit	Ordinary profit	Profit for the six months	Basic earnings per share
Previous forecast (A)	251,900	12,800	12,200	8,400	71.83 yen
Revised forecast (B)	251,900	12,800	18,200	14,400	123.11 yen
Change (B – A)	0	0	6,000	6,000	
Percentage change	0.0%	0.0%	49.2%	71.4%	
(Reference) Results for the same period of the previous fiscal year (six months ended September 30, 2024)	239,882	12,141	11,805	8,140	69.60 yen

2. Revised non-consolidated financial forecasts for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026)

(Units: million yen, %)

	Net sales	Operating profit	Ordinary profit	Profit for the current fiscal year	Basic earnings per share
Previous forecast (A)	510,000	27,100	26,000	18,000	153.92 yen
Revised forecast (B)	510,000	27,100	35,000	27,000	230.84 yen
Change (B – A)	0	0	9,000	9,000	
Percentage change	0.0%	0.0%	34.6%	50.0%	
(Reference) Results for the previous fiscal year (ended March 31, 2025)	485,758	25,587	24,823	17,588	150.38 yen

3. Reason for the revision

As announced on August 7, 2025, the Company began to receive dividends from consolidated subsidiaries from the fiscal year ending March 31, 2026. The receipt of dividends will increase the non-consolidated profit (drugstore business) and exceed the initial estimates. Accordingly, the Company has revised the estimated profit upward. Separately, as the Company will begin to receive interim dividends from consolidated subsidiaries in December 2025, the change of the non-consolidated profit for the fiscal year ending March 31, 2026 is expected to be 9,000 million yen. However, the revision of the non-consolidated financial forecasts will not affect the consolidated financial forecasts and results.

(Note) The above-mentioned forecasts of performance are based on the information available as of the date of this announcement. Actual results may differ from the forecasts due to various factors going forward.